Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women ages 18 and older;
Willing to provide written informed consent;
Must have uncontrolled hypertension defined as: currently untreated with a diastolic blood pressure greater than 110 mmHg OR currently receiving antihypertensive monotherapy with a diastolic blood pressure greater than 100 mmHg. Monotherapy is defined as treatment with one antihypertensive medication for at least four weeks; fixed combination therapy does not represent monotherapy;
Must be willing to discontinue antihypertensive medication, if applicable;
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized.
WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication.
You may not be if
Women who are pregnant or breastfeeding;
Known or suspected secondary hypertension;
Hypertension emergencies or stroke within the past 12 months;
Heart attack, angina or bypass surgery within the past 6 months;
Significant kidney disease;
Significant liver disease;
Systemic lupus erythematosus;
Gastrointestinal disease or surgery that may interfere with drug absorption;
Cancer during the past five years excluding localized squamous cell or basal cell carcinoma of the skin;
Currently pregnant or lactating;
Mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope, and possible consequences of the study;
Drug or alcohol abuse within the last five years;
Known allergy to irbesartan or diuretics.
Clareo Health | Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
